CoGenesis® Prostate

CoGenesis® Prostate is a germline genetic test designed for men with personal or family histories suggestive of inherited prostate cancer risk. Rather than evaluating one gene at a time, this panel analyzes 16 clinically relevant hereditary cancer genes in a single assay. The panel includes key DNA-repair and hereditary risk genes such as BRCA1, BRCA2, ATM, CHEK2, PALB2, and HOXB13, as well as Lynch syndrome-associated genes (MLH1, MSH2, MSH6) and other prostate-risk genes.

A positive result may help explain family clustering of prostate cancer and guide next-step management, including earlier or more intensive surveillance, specialist referral, treatment planning discussions, and cascade testing for at-risk relatives. A negative result can lower suspicion of a known inherited cause but does not fully exclude hereditary risk, especially when family history remains strongly suggestive. Clinical interpretation should therefore integrate personal history, pathology, family pedigree, and genetic counseling.

• Men with personal or family history suggestive of hereditary prostate cancer.
• Men diagnosed at a younger age or with multiple affected first-degree relatives.
• Patients and clinicians who need germline information to support risk stratification and follow-up planning.
• Families considering cascade testing after a clinically significant finding.
• Multidisciplinary review when hereditary findings may influence treatment and surveillance decisions.

4mL Peripheral blood (EDTA), 2mL saliva, or buccal swab

Preferred sample type:

• 4mL Blood (EDTA tube),
• Codex-provided buccal swabs (4 swabs)
• Codex-provided saliva collection kit (2mL)

Saliva or buccal swab sample collection: Follow the enclosed instructions; do not eat, drink, or smoke for 30 minutes before collection.

• Results may identify pathogenic, likely pathogenic, or variants of uncertain significance (VUS).
• Positive findings can inform risk‑reducing strategies and treatment options.
• Genetic counseling is recommended to help families understand implications.

A subset of prostate cancer is driven by inherited germline variants, especially in genes involved in DNA damage response and mismatch-repair pathways. Hereditary risk can be higher in men with early-onset disease, multiple affected first-degree relatives, or family history overlapping with breast, ovarian, pancreatic, or Lynch-spectrum cancers.

A focused hereditary prostate panel helps identify clinically meaningful germline variants that can guide downstream management. Depending on the gene identified, guideline-informed care may include earlier surveillance initiation, tailored follow-up intensity, family risk counseling, and referral for cascade testing in relatives.